Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GE Healthcare signs “exclusive” distribution agreement

GE Healthcare signs “exclusive” distribution agreement

25th May 2006

The UK-based GE Healthcare has said it has signed an “exclusive” agreement with DiscoveRx for all HitHunter cAMP Enzyme Fragment Complementation drug screening system, a DiscoveRx product.

The HitHunter cAMP is a non-radioactive assay (a system of defining the concentration of a component of a mixture) that can scan microplate samples for the activation of G-protein coupled receptors, which play an important part in cell signalling and are targets for drug discovery, according to GE Healthcare.

As part of the deal, GE Healthcare will also distribute DiscoveRx’s kinase assays in the Asia Pacific area.

Ger Brophy, general manager of discovery sciences at GE Healthcare, stated: “We are already known for our SPA screening products – adding the DiscoveRx portfolio allows us to offer a more comprehensive suite of screening technologies to our customers, combined with the high quality and service they have come to expect.”

DiscoveRx’s chief executive officer added: “We are tremendously excited about this important step forward, which broadens the global access of our HitHunter products through a premier supplier of life science research tools.”

GE Healthcare is headquartered in Chalfont St Giles in Buckinghamshire. It describes itself as a $15 billion (eight billion pounds) subsidiary of General Electric that specialises in a variety of fields, including imaging, diagnostics, drug discovery and biopharmaceutical technology development. DiscoveRX is a Californian business which also has UK offices in Birmingham.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.